The role of microRNA‐5196 in the pathogenesis of systemic sclerosis

Abstract

These results suggest that microRNA-5196 can be used as a potential biomarker characterising SSc. Overall, this study may open new possibilities for the development of microRNA-5196-based diagnostics and therapy in early phases of SSc.

Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients

“…2 ). Similar to the previously published results (Ciechomska et al 2017 ), we have also seen increased expression of miRNA-5196 in SSc sera (Fig. 1 ).…”

“…These molecules play an important role in inflammation and progression of rheumatic diseases (Araki and Mimura 2017 ; Dey et al 2016 ; Magyari et al 2014 ). Indeed, in the previous paper we have shown that miRNA-5196 targets Fra2 and subsequently reduces profibrotic TIMP-1 production in SSc monocytes (Ciechomska et al 2017 ). MiRNA-5196 binds to five seed regions within 3′UTR of Fra2, therefore, can negatively regulate gene expression of target mRNA (Ciechomska et al 2017 ).…”

“…Indeed, in the previous paper we have shown that miRNA-5196 targets Fra2 and subsequently reduces profibrotic TIMP-1 production in SSc monocytes (Ciechomska et al 2017 ). MiRNA-5196 binds to five seed regions within 3′UTR of Fra2, therefore, can negatively regulate gene expression of target mRNA (Ciechomska et al 2017 ). Thus, we sought to investigate whether miRNA-5196 could be used as a novel biomarker for predicting anti-TNF-α therapy in RA and AS patients.…”

“…Since we have previously demonstrated that the level of miRNA-5196 is increased in sera and monocytes isolated from SSc patients compared to HC (Ciechomska et al 2017 ), we sought to investigate the level of miRNA-5196 in sera from RA and AS patients to determine whether circulating miRNA-5196 can be used as a potential biomarker of rheumatic diseases. As a positive control of increased miRNA-5196 expression we used SSc sera.…”

Assessment by miRNA microarray of an autologous cancer antigen‐pulsed adoptive immune ensemble cell therapy (AC‐ACT) approach; demonstrated induction of anti‐oncogenic and anti‐PD‐L1 miRNAs

“…These types of personalized, individualized medicine approaches where miRNA profiling is monitored for each patient to develop a unique picture of progression after therapy may have more value than attention to normalized or population‐based metrics of therapy effectiveness and progression. Notably, the most significantly decreased miRNA in response to AC‐ACT was miR‐5196‐5p, which targets the Fra2 gene, plays a critical role in the progression of human cancers, and it is involved in IL‐4 production for tumor immunity suppressor . Reduction in miR‐5196‐5p by AC‐ACT may suppress cancer progression but also immune potency will be inhibited.…”